Jazz’s development pipeline includes the clinical development of new therapies to treat unmet medical needs, line extensions for existing products, and the generation of additional clinical data for existing products.
1 NDA submission assumes positive outcomes.
2 JZP-386 formulation work ongoing.
3 The company has made the decision to discontinue development of two early-stage Celator programs, CPX-1 and CPX-8.
ES = Excessive Sleepiness, OSA = Obstructive Sleep Apnea, NDA = New Drug Application, EDS = Excessive Daytime Sleepiness, sNDA = Supplemental New Drug Application, BE = Bioequivalence, EU = European Union, AML = Acute Myeloid Leukemia , VOD = Hepatic Veno-occlusive Disease, HSCT = Hematopoietic Stem Cell Transplantation